CYSTEINE RESIDUES IN THE VIF PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ARE ESSENTIAL FOR VIRAL INFECTIVITY

被引:58
|
作者
MA, XY
SOVA, P
CHAO, W
VOLSKY, DJ
机构
[1] ST LUKES ROOSEVELT HOSP,MOLEC VIROL LAB,NEW YORK,NY 10019
[2] COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032
关键词
D O I
10.1128/JVI.68.3.1714-1720.1994
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The infectivity factor of human immunodeficiency virus type 1 (HIV-1), Vif, contains two cysteine residues which are highly conserved among animal lentiviruses. We introduced substitutions of leucine for cysteine residues in the vif gene of a full-length HIV-1 clone to analyze their roles in viral infection. Mutant viruses containing substitutions in either Cys-114, Cys-133, or both displayed a vif-negative infection phenotype similar to that of an isogeneic vif deletion mutant, namely, a cell-dependent complete to partial loss of infectivity. The vif defect could be complemented by cotransfection of mutant viral DNA with a Vif expression vector, and there was no evidence that recombination contributed to the repair of the vif deficiency. The viral protein profile, as determined by immunoblotting, in cells infected with cysteine substitution mutants and that in wild-type virus were similar, including the presence of the 23-kDa Vif polypeptide. In addition, immunoblotting with an antiserum directed against the carboxyl terminus of gp41 revealed that gp41 was intact in cells infected with either wild-type or vif mutant HIV-1, excluding that Vif cleaves the C terminus of gp41. Our results indicate that the cysteines in HIV-1 Vif are critical for Vif function in viral infectivity.
引用
收藏
页码:1714 / 1720
页数:7
相关论文
共 50 条
  • [41] CELLULAR LATENCY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    POMERANTZ, RJ
    BAGASRA, O
    BALTIMORE, D
    CURRENT OPINION IN IMMUNOLOGY, 1992, 4 (04) : 475 - 480
  • [42] INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY ALCOHOLS
    VANBUEREN, J
    LARKIN, DP
    SIMPSON, RA
    JOURNAL OF HOSPITAL INFECTION, 1994, 28 (02) : 137 - 148
  • [43] HEADACHE AND THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    HOLLOWAY, RG
    KIEBURTZ, KD
    HEADACHE, 1995, 35 (05): : 245 - 255
  • [45] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND CYTOMEGALOVIRUS IN SALIVA
    LUCHT, E
    ALBERT, J
    LINDE, A
    XU, WM
    BRYTTING, M
    LUNDEBERG, J
    UHLEN, M
    BRATT, G
    SANDSTROM, E
    HEIMDAHL, A
    NORD, CE
    WAHREN, B
    JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (02) : 156 - 162
  • [46] RENAL COMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    BOURGOIGNIE, JJ
    KIDNEY INTERNATIONAL, 1990, 37 (06) : 1571 - 1584
  • [47] STRUCTURE AND FUNCTION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    PAVLAKIS, GN
    SEMINARS IN LIVER DISEASE, 1992, 12 (02) : 103 - 107
  • [48] SEQUENTIAL DETERMINATION OF VIRAL LOAD AND PHENOTYPE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    DAAR, ES
    CHERNYAVSKIY, T
    ZHAO, JQ
    KROGSTAD, P
    CHEN, ISY
    ZACK, JA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (01) : 3 - 9
  • [49] MULTIPLE EFFECTS OF MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INTEGRASE ON VIRAL REPLICATION
    ENGELMAN, A
    ENGLUND, G
    ORENSTEIN, JM
    MARTIN, MA
    CRAIGIE, R
    JOURNAL OF VIROLOGY, 1995, 69 (05) : 2729 - 2736
  • [50] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TROPISM FOR HUMAN MACROPHAGES
    COLLMAN, R
    PATHOBIOLOGY, 1992, 60 (04) : 213 - 218